The FDA Center for Drug Evaluation and Research, has released a statement that, “by early December, FDA plans to submit our formal recommendation package to HHS to reclassify hydrocodone combination products [including Vicodin] into Schedule II. Read more here.

AAOMS and the ADA had issued a joint statement to the FDA when they were deliberating on this reclassification.  Read that statement here.

Topics: None